Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 17/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617264 | 0.92 | SLC6A9 (0.56) | SLC6A9KCNH2HTR1AHTR7 | |
| SCHEMBL617038 | 0.92 | SLC6A9 (0.59) | SLC6A9KCNH2 | |
| SCHEMBL605890 | 0.90 | SLC6A9 (0.59) | SLC6A9KCNH2HTR1AHTR7SLC8A1 | |
| SCHEMBL616747 | 0.90 | SLC6A9 (0.57) | SLC6A9KCNH2HTR1AHTR7 | |
| SCHEMBL616460 | 0.88 | SLC6A9 (0.55) | SLC6A9KCNH2HTR1AHTR7 | |
| SCHEMBL616055 | 0.88 | SLC6A9 (0.46) | SLC6A9KCNH2HTR1AHTR7SLC8A1 | |
| SCHEMBL614180 | 0.87 | SLC6A9 (0.44) | SLC6A9KCNH2ALDH1A1 | |
| SCHEMBL617756 | 0.86 | SLC6A9 (0.71) | SLC6A9KCNH2 | |
| SCHEMBL615081 | 0.85 | SLC6A9 (0.47) | SLC6A9KCNH2HTR1AHTR7SLC8A1 | |
| SCHEMBL603032 | 0.85 | SLC6A9 (0.66) | SLC6A9KCNH2HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051280-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-09 | — | — | US | claimed |
| EP-2709987-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2014-03-26 | — | — | EP | claimed |
| WO-2012020133-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | claimed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | disclosed |
| WO-2012020133-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC10A1, SUGT1, SLC10A2 | SLC6A9 42/4885KCNH2 1552/4885HTR1A 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.